Qiagen NV
Open
$33.94
Prev. Close
$33.94
High
$33.97
Low
$33.93
Market Snapshot
$7.32B
17.2
0.36
$1.98B
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
emptyResult
QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company is headquartered in Venlo, Limburg and currently employs 5,654 full-time employees. The firm is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials. Its assay technologies make these biomolecules visible for analysis, such as identifying the genetic information of a pathogen or a gene mutation in a tumor. Its bioinformatics solutions interpret data to provide actionable insights. The firm's automation platforms based on polymerase chain reaction (PCR), next-generation sequencing (NGS) and other technologies tie these together in molecular testing workflows from Sample to Insight.
Recently from Cashu
Deutsche Bank Upgrades Qiagen NV, Highlights Recovery Amid Market Volatility
Qiagen NV's Analyst Upgrades Signal Recovery Potential Amidst Market Volatility In recent developments, Deutsche Bank upgrades Qiagen NV to a 'buy' rating, a significant shift considering the company’…
Analyst Upgrade Reaffirms Qiagen's Potential for Recovery Amid Market Challenges
Strategic Upgrade Positions Qiagen for Recovery Amid Market Fluctuations Recent analyst activity highlights significant movements for Qiagen NV, particularly following an upgrade from Deutsche Bank th…
Qiagen NV: Leading Innovation in Diagnostic Testing and Industry Adaptation
Qiagen NV: Pioneering Advances in Diagnostic Testing Amid Industry Developments In the rapidly evolving field of molecular diagnostics, Qiagen NV stands at the forefront of innovation, with a strong e…
Avantor's Earnings Report: Implications for Qiagen NV and Life Sciences Growth
Avantor’s Upcoming Earnings Report Signals Strategic Growth in Life Sciences Avantor (NYSE:AVTR) prepares to unveil its quarterly earnings report on October 29, 2025, marking a pivotal moment for the…